Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature.

Our data provide further evidence supporting the effectiveness of mepolizumab in allergic bronchopulmonary aspergillosis because it decreases the dose of oral corticosteroids and the rate of exacerbations, and improves asthma control and quality of life.